A new device for measurement of fibrin clot lysis: Application to the Euglobulin Clot Lysis Time

被引：28

作者：

Zouaoui Boudjeltia K. ^{[1
]}

Cauchie Ph. ^{[1
]}

Remacle Cl. ^{[3
]}

Guillaume M. ^{[2
]}

Brohée D. ^{[1
]}

Hubert J.L. ^{[4
]}

Vanhaeverbeek M. ^{[1
]}

机构：

[1] Laboratoire Medecine Experimentale, Universite de Libre de Bruxelles, Hôpital A. Vésale, Montigny-le-Tilleul

[2] Departement de Cardiologie, Montigny-le-Tilleul

[3] Laboratoire de Biologie Cellulaire, Univ. Catholique de Louvain-La-Neuve, Louvain-La-Nueve

[4] EREM SA Company, Marcinelle

来源：

BMC Biotechnology | / 2卷 / 1期

关键词：

Efficiency Score; Fibrinogen Level; Venous Occlusion; Clot Lysis; Lysis Time;

D O I：

10.1186/1472-6750-2-8

中图分类号：

学科分类号：

摘要：

Background: Determination of clot lysis times on whole blood, diluted whole blood, plasma or plasma fraction has been used for many years to assess the overall activity of the fibrinolytic system. We designed a completely computerised semi-automatic 8-channel device for measurement and determination of fibrin clot lysis. The lysis time is evaluated by a mathematical analysis of the lysis curve and the results are expressed in minute (range: 5 to 9999). We have used this new device for Euglobulin Clot Lysis Time (ECLT) determination, which is the most common test used in laboratories to estimate plasma fibrinolytic capacity. Results: The correlation between ECLT and manual method is very tight : R = 0,99; p < 10-6. The efficiency scores of the method are <4% in intra-assay and <7% in inter-assay. It allows to achieve the tests on hyperlipaemic samples. This new device has been easily integrated in laboratory routine and allows to achieve several ECLT every day without disturbance of laboratory workflow. Conclusions: The routine use of this new device could be useful in various situations such as assessment in atherosclerosis and arteriosclerosis associated diseases, coagulation survey of liver transplantations, cardiovascular surgery or pharmacological research. It has already provided highly promising results in preliminary studies on the relation between fibrinolysis and cardiovascular risk factors. © 2002 Boudjeltia et al; licensee BioMed Central Ltd.

引用

页数：9

共 21 条

[1]

Bjorn W., The fibrinolytic enzyme system: Basic principles and links to venous and arterial thrombosis, Hematol. Oncol. Clin., 14, pp. 325-338, (2000)

[2]

Booth N.A., Fibrinolysis and thrombosis, Baillieres Best Pract. Res. Clin. Haematol., 12, pp. 423-433, (1999)

[3]

Hadjez J.M., Combe S., Horellou M.H., Conard J., Nguyen G., Van Dreden P., Samama M., Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with history of venous thrombosis, Fibrinolysis, 8, pp. 87-95, (1994)

[4]

Hiraga T., Shimada M., Tsukada T., Murase T., Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system, Horm. Metab. Res., 28, pp. 603-606, (1996)

[5]

Lowe G., Coagulation, fibrinolysis and cardiovascular disease, Fibrinolysis Proteolysis, 13, pp. 91-98, (1999)

[6]

Juhan-Vague I., Collen D., On the role of coagulation and fibrinolysis in atherosclerosis, Ann. Epidemiol., 4, pp. 427-438, (1992)

[7]

Juhan-Vague I., Valadier J., Alessi M.C., Aillaud M.F., Ansaldi J., Philip-Joet C., Holvoet P., Serradimigni A., Collen D., Deficient t-PA release and elevated PAI-1 in patient with spontaneous or recurrent deep venous thrombosis, Thromb. Haemost., 57, pp. 67-72, (1987)

[8]

Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Hennekens C.H., Endogenous tissue-type plasminogen activator and risk of myocardial infarction, Lancet, 341, pp. 1165-1168, (1993)

[9]

Jespersen J., Bertina R.M., Haverkate F., Ecat Assay Procedures

[10]

A Manual of Laboratory Techniques, pp. 125-129, (1992)

← 1 2 3 →